Women in the United States are largely uninformed when it comes to some critical health issues, including their relatively higher risk of developing Alzheimer’s disease as compared to men, according to a comprehensive survey about the state of women’s health. Results of the survey conducted by the Women’s Alzheimer’s Movement…
ALPHA-1062, Alpha Cognition’s investigational oral tablet for mild to moderate Alzheimer’s disease, may be a bioequivalent substitute for the approved therapy Razadyne, according to a pivotal trial with healthy volunteers. The pro-drug therapy — meaning that the medication is metabolized in the body, after administration — showed positive…
Early treatment with crenezumab, an investigational anti-amyloid antibody, failed to significantly slow or prevent cognitive decline in a group of people with a genetic risk for early-onset Alzheimer’s disease, data from a Phase 2 trial show. Numerical differences favoring crenezumab over a placebo were seen across…
A Phase 2 clinical trial will test BMND08, an investigational oral therapy based on a natural psychedelic, in treating depression and anxiety in people with Alzheimer’s disease, its developer, Biomind Labs, reported. The company’s announcement follows the trial’s approval by an institutional review board in Argentina.
Hoth Therapeutics and Washington University have agreed to extend preclinical research into HT-ALZ, Hoth’s experimental therapy for Alzheimer’s disease. Research findings are expected to be helpful in estimating the best dose of HT-ALZ to test in potential clinical trials, according to a company press release. Hoth entered into…
Caring for a loved one with Alzheimer’s disease (AD) can be overwhelming. To help ease the caregiver burden — and ultimately benefit patients — a Florida-based company called VirtuALZ is offering a new virtual support program. Crafted specifically to support caregivers of patients who have Alzheimer’s and related…
UsAgainstAlzheimer’s is preparing to launch free online courses — The Brain Health Academy — teaching health and wellness professionals how to help people reduce the risk of Alzheimer’s and dementia. Developed in partnership with the American Heart Association, The American College of Lifestyle Medicine, and the Centers for…
Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will…
An innovative new project in Toronto will combine optometry and community-based cognitive testing to improve Alzheimer’s screening and enable the early detection of the progressive neurodegenerative disorder. The project — launching in Ontario, Canada — will be led by the medical imaging company RetiSpec and the community-based medical center…
The start of summer holds the promise of beach trips, barbecues, and vacations, but for people with Alzheimer’s disease and their caregivers, family, and friends, June also means Alzheimer’s and Brain Awareness Month. Monthlong initiatives aim to honor the more than 55 million people living with dementia worldwide, according…
Get regular updates to your inbox.